key: cord-0335756-no3bj0wo
authors: Sánchez-Martínez, Diego; Tirado, Néstor; Mensurado, Sofia; Martínez-Moreno, Alba; Romecin, Paola; Gutiérrez-Agüera, Francisco; Correia, Daniel V; Silva-Santos, Bruno; Menéndez, Pablo
title: Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia
date: 2022-03-17
journal: bioRxiv
DOI: 10.1101/2022.03.15.484289
sha: ea6fb9065d6e514171e7b4324af0f79c2754a8c8
doc_id: 335756
cord_uid: no3bj0wo

Chimeric Antigen Receptor (CAR)-T cells have emerged as a breakthrough treatment for relapse/refractory (r/r) hematological tumors, showing impressive complete remission rates in B-cell malignancies. However, around 50% of the patients relapse before 1-year post-treatment. T-cell “fitness” is critical to prolong the persistence and activity of the adoptively transferred product. Allogeneic T cells from healthy donors are less dysfunctional or exhausted than autologous patient-derived T cells, enabling a very attractive and cost-effective “off-the-shelf” therapy option. In this context, Delta One T cells (DOTs), a recently described cellular product based on MHC/HLA-independent Vδ1+ γδ T cells generated from the peripheral blood of healthy donors, represent a robust platform of allogeneic effector T cells. Here we generated and pre-clinically validated 4-1BB-based CAR-DOTs directed against the IL-3α chain receptor (CD123), a target antigen widely expressed on acute myeloid leukemia (AML) blasts. CD123CAR-DOTs showed vigorous, superior to control DOTs, cytotoxicity against AML cell lines and primary samples both in vitro and in vivo. Continuous administration of IL-15 supported the long-term persistence of a single-dose CD123CAR-DOTs in patient-derived xenograft models, sustaining their anti-leukemic efficacy as demonstrated in a re-challenge assay in vivo. Our results provide proof-of-concept for an allogeneic next-generation therapy based on CD123CAR-DOTs for r/r AML patients. KEY POINTS - CD123CAR-DOTs exert specific and robust cytotoxicity in vitro and anti-leukemic activity in vivo against AML cell lines and primary cells. - CD123CAR-DOTs show IL-15-dependent long-term persistence in vivo and vigorous anti-leukemic activity upon re-challenge.

Immunotherapy has promoted marked improvements in cancer treatment over the last decade. The immune system offers a wide range of alternatives, including cytotoxic lymphocytes -native or engineered -to eliminate treatment-resistant tumors. In this context, CD19-directed chimeric antigen receptor (CAR)transduced T cell (CAR-T) therapies have shown impressive rates of complete remissions (CR) in relapse/refractory (r/r) B-cell malignancies, especially in B-cell acute lymphoblastic leukemia (ALL). However, one-year progression-free survival remains 50% due to frequent relapses 3, 4 . Antigen loss and phenotypic escape as well as CAR-T cell disappearance, dysfunctionality or exhaustion are commonly responsible for such failures 5, 6 . Thus, new therapeutic options based on "fitter" effector T cells are being actively investigated in order to increase T-cell persistence and efficacy.

Allogeneic cytotoxic cells obtained from healthy donors (HD) are an especially attractive avenue for "off-theshelf" next-generation CAR-T cell therapies. In particular, MHC/HLA-independent T cells have emerged as a promising candidate based on their potent cytotoxic activity and release of cytokines stimulating and recruiting other immune cells to the tumor site [7] [8] [9] . While the low abundance of  T cells in the human peripheral blood (PB) has hindered their clinical application, recent advances in protocol development have enabled their ex vivo expansion to large numbers [10] [11] [12] [13] . In particular, we have characterized Delta One T (DOT) cells, a Vδ1 T cell-enriched cellular product expressing enhanced levels of natural cytotoxicity receptors (NCRs), and demonstrated that they constitute a safe and efficient effector platform to eliminate cancer cells in in vitro and in vivo pre-clinical models of solid and hematological malignancies 10 , most notably acute myeloid leukemia (AML) 14 .

AML, the most common acute leukemia in adults, is characterized by the accumulation of differentiationdefective immature and proliferative myeloid blasts in the bone marrow (BM) and PB 15 . Unfortunately, patient overall survival has not improved significantly over the last decades, with relapses being frequent and presenting poor outcome, thus requiring hematopoietic stem cell transplantation (HSCT) as rescue therapy 16 .

Despite its molecular enormous heterogeneity 15, 17, 18 , CD123, the  chain of the interleukin (IL)-3 receptor, is consistently expressed in >90% of AML blasts, in similar levels to leukemic stem cells, and its expression is maintained at relapse 19, 20 . Based on this rational, we previously showed robust efficacy of second generation (4-1BB-based) CD123-directed CAR-T cells in preclinical AML models 21 .

Clinical implemented CAR-T cell approaches are based on abundant αβ T cells [22] [23] [24] which have a limited applicability to the allogeneic setting due to their MHC/HLA restriction and graft-versus-host potential 25 .

Importantly, an immunological BM dysfunction and T-cell exhaustion has been reported in intensively chemotherapy-treated r/r AMLs 26 . Thus, safety allowing, allogeneic T cells from HDs would represent an "offthe-shelf" cost-efficient therapy option to eliminate r/r AML. Building on these foundations, we prompted to explore the potential of MHC/HLA-independent DOT cells as vehicle for our second generation CD123 CAR in preclinical AML models.

Here we describe, for the first time, the generation of CAR-expressing DOT cells (CAR-DOTs), and provide the proof-of-concept for their application in AML treatment. Retrovirally-transfected CD123CAR-DOTs potently eliminated AML cell lines and primary samples both in vitro and in vivo, increasing the efficacy of "naked" (mock-transduced) DOTs in different models and conditions, without phenotypic alterations.

Moreover, CD123CAR-DOTs released type 1 (anti-tumor) cytokines and chemokines upon exposure to primary AML cells. In in vivo rechallenge experiments, CD123CAR-DOTs persisted and remained functional against AML, nine weeks after their infusion into mice. IL-15 significantly improved their in vivo efficacy by sustaining longer action and enabling one-single-dose treatment. Our data demonstrate the potential of CAR-DOTs to represent a disruptive "off-the-shelf" allogeneic cellular immunotherapy for AML.

PB mononuclear cells (PBMCs) were isolated from buffy coats from HDs by Ficoll-Hypaque gradient centrifugation. Buffy coats were obtained from the Barcelona Blood and Tissue Bank (BST) upon IRBapproval (HCB/2018/0030). PBMCs were incubated with anti-TCR Biotin mAb (Miltenyi Biotec) followed by incubation with anti-Biotin mAb microbeads to deplete T-cells by magnetic separation using AUTOMACS under depleteS protocol (Miltenyi Biotec, Biergisch Gladbach, Germany). DOT cells were generated from -depleted PBMCs cultured in either 96-well plates or G-REX platform (Wilson Wolf Manufacturing), based on an adaptation from our previous protocol 10, 14 . Briefly, αβdepleted PBMCs were resuspended in OpTmizer-CTS medium supplemented with 2.5% heatinactivated human plasma (LifeSciences), 2 mmol/L L-glutamine (Thermo Fisher) and 50 U/mL/50 ug/mL of Penicillin/Streptomycin (Thermo Fisher) and cultured for 16-20 days. Animal-free human cytokines rIL-4 (100 ng/mL), rIFN (70 ng/mL), rIL-21 (7 ng/mL), and rIL1β (15 ng/mL; all from PeproTech), and a soluble mAb anti-CD3 (clone OKT-3, 140 ng/mL; BioLegend), were added to the medium at day 0. At day 7, cultures were supplemented with anti-CD3 (clone OKT-3, 1 g/mL or 2g/mL for 96-well plate protocol), rIL-21 (13 ng/mL) and rIL-15 (70 ng/mL; also from PrepoTech). On day 11, new medium was added to cultures, supplemented with anti-CD3 (1 g/mL) and rIL-15 (100 ng/mL). Cells were incubated at 37 ºC and 5% CO2. DOT cells were harvested at the end of the culture and either used fresh (for in vitro assays) of cryopreserved (for in vivo experiments) in OpTmizer media + 20% human plasma + 10% DMSO and stored in liquid nitrogen.

To construct the retroviral transfer vector, the complete CD123-directed CAR (including CSL362 scFv, CD8 transmembrane domain, 4-1BB costimulatory domain, CD3z endodomain, and a T2A-eGFP cassette) previously described 21 was cloned into an SFG retroviral backbone. The SFG vector expressing eGFP alone (mock vector) was used as a control. Viral particles pseudotyped with RD114 were generated using 293T 29 . CAR-or mock-DOTs were thawed and resuspended in complete media and mice were i.v. infused in the tail vein with 10×10 6 cells once, twice or three times 7-, 14-and 21-days post-tumor inoculation, respectively. Where indicated, mice were injected intraperitoneally with 1g of hrIL15 every 3-4 days or daily from day 7 to the end of the experiment, as a strategy to support DOT-cell persistence in vivo.Tumor burden was followed by bioluminescence (BLI) using the Xenogen IVIS 50 Imaging System (Perkin Elmer). To measure luminescence, mice received 150 mg/kg of D-luciferin intraperitoneally, and tumor burden was monitored at the indicated time points as we previously described 27, 30 . Living Image software (Perkin Elmer) was used to visualize and calculate total luminescence. Besides, tumor burden was followed-up at different timepoints by bleeding and BM aspirate using FACS analysis. Mice were sacrificed when control and/or mock-DOT-treated animals were leukemic, and tumor burden (hHLA-ABC + hCD45 + hCD33 + hCD123 + graft) and effector DOT persistence (hHLA-ABC + hCD45 + hCD3 + V1 + ) were analysed in BM and PB by FACS. In re-challenge experiments, leukemia-free animals were re-infused with 2.5×10 5 CD123+ AML primary cells, and disease reappearance was followed-up by BLI and FACS as above. All procedures were performed in compliance with the institutional animal care committee of the PRBB (DAAM9624).

Data from at least three individual donors are shown in all figures. All p-values were calculated by unpaired two-tailed or one-tailed Student's t-test using Prism software (GraphPad). A p-value *<0.05/**<0.01/***<0.001/****<0.0001 was considered statistically significant.

For original data, please contact dsanchez@carrerasresearch.org

We set out to generate, for the first time, CAR-DOT cells, and purpose them for AML targeting. DOT cells were expanded and activated as described 10, 14 , and transduction was tested at days 7 and 11 using different retroviral (PeqPam/RD114) and lentiviral (VSV-G/psPAX2) conditions ( Fig S1) . Retro-X Concentrator at day 7 showed the highest rate of anti-CD123 CAR expression and was chosen for downstream generation of CD123CAR-DOTs (Fig 1A) . CD123CAR transduction/expression did not impact  TCR  and V1  T cell percentages, which were ~97% and ~70% respectively, as in the original "naked" DOT product 10, 14 . Likewise, total and V1  T-cell numbers at the end of the process were similar for mock-and CAR-DOTs ( Fig 1C) .

Retroviral particles infected the V1  and V1   T-cell populations in similar proportions, and the CD123CAR expression as determined by GFP positivity correlated well with anti-ScFv labelling ( Fig. 1B, C) . (>90%) > DNAM-1 (~60%) > NKp30 and NKp44. By contrast, the immune checkpoint PD-1 was strikingly absent from both DOT populations (Fig. 1E) . The expression of the key components of cytotoxic granules, perforin (Perf), granzyme (Gzm) A and GzmB, was also not affected by CAR transduction (Fig 1F) .

Collectively, these data demonstrate the feasibility of CAR-DOT generation, and further show that retroviral infection and CD123CAR expression on the cell surface does not modify DOT expansion properties or phenotype, thus generating NK-like cytotoxic effector  T cells highly enriched in V1 + T cells.

In order to test the anti-AML activity of CAR-DOTs, we performed in vitro cytotoxicity assays against the CD123  AML cell lines MOLM13 and THP-1, and the CD123  T-cell acute lymphoblastic leukemia line, Jurkat, as negative control. CD123CAR-DOTs specifically eliminated CD123  AML cells in an E:T ratiodependent manner, with substantially increased cytotoxic activity compared to mock-DOTs. Even at low E:T ratios (1:16, 1:8, 1:4) we achieved 20-60% more AML cell lysis than with mock-DOTs in 48h and 24h assays (Fig 2A, S2) . Next, to evaluate their capacity to kill primary tumors, CD123CAR-DOTs were co-cultured with primary CD123 + AML samples, with different percentages of CD123  CD33  blasts (Fig 2B) . and leukemia progression was followed by BLI (Fig 3A) . CD123CAR-DOTs controlled AML tumor burden between days 20 and 47 significantly better than mock-DOTs which only managed to delay tumor growth and could not prevent an eventual logarithmic tumor growth from day 47 onwards (Fig 3B) . At this point, we decided to provide an additional 4 th infusion at day 53, which resulted in complete control of leukemia in CD123CAR-DOT mice, in stark contrast with continued tumor growth in mock DOT-treated mice (Fig. 3B) .

Leukemic burden, as determined by HLA-ABC/CD45/CD123/CD33 expression, showed high, intermediate and absent blast cells in untreated, mock-DOT and CAR-DOT-treated mice, respectively (Fig. 3C) . These data highlight the therapeutic advantage over 12 weeks of CD123CAR-DOTs over mock-DOTs in in vivo AML-PDX models.

Having achieved the initial proof-of-concept for CD123CAR-DOT activity in AML xenografts, we next aimed to maximize it through provision of key DOT survival factors, particularly since the murine milieu lacks human cytokines. Given that the DOT protocol relies on IL-15 as the critical cytokine in the second stage of expansion/ differentation 10,14 , we combined CD123CAR-DOTs with i.p. IL-15 administration every 3-4 days.

In this set of experiments, NSG mice were transplanted with 2.5×10 5 AML-PDX LUC cells, and starting one week later, they received one, two or three doses of 10×10 6 CD123CAR-DOTs, with or without IL-15 injection ( Fig 4A) . Leukemia engraftment was followed weekly by BLI and by flow cytometry analysis of BM and PB samples. In the absence of exogenous IL-15, three doses of CD123CAR-DOT (CAR3) were clearly more efficacious than one (CAR1) or two (CAR2) doses, since these only managed to delay tumor burden (compared to untreated control mice) (Fig 4B,C) . Strikingly, the provision of IL-15 every 3-4 days overrode all such differences, thus allowing complete leukemia control 60 days after even with a single CD123CAR-DOT infusion (Fig 4B,C) . These results demonstrate a critical adjuvant effect of exogenous IL-15 on CD123CAR-DOT therapy in AML-PDX in vivo.

Building on the observed major impact of IL-15 on CD123CAR-DOT activity, we decided to evaluate side-byside how IL-15 provision, in various regiments, would boost single-dose CD123CAR-DOT versus mock-DOT activities in vivo. In this experimental design, CD123CAR-DOTs or mock-DOTs were infused (in a singleone dose) one week after i.v. injection of 2.5×10 5 AML-PDX LUC cells, followed by 3 different IL-15 administration regimens: daily, every 3-4 days, or none at all (Fig 5A) . Strikingly, mock-DOTs plus daily IL-15 showed similar leukemia control to all groups of CD123CAR-DOT-treated mice, as evaluated by BLI up to day 42 (Fig 5B,C) . The daily provision of IL-15 was critical to enhance mock-DOT cell activity, since the 3-4-day IL-15 regimen barely reduced tumor burden compared to control groups (Fig 5B,C) . These data were consolidated by flow cytometry analysis of BM aspirates, which showed that AML cell engraftment correlated with IVIS imaging (Fig 5D) . Importantly, the infused (CAR-or mock-) DOTs were only detected in the BM at the endpoint of the experiment when daily IL-15 was administered, thus highlighting the importance of in vivo persistence of the effector T cells (Fig 5E,F) . These data unveil the importance of in vivo IL-15 administration regimens on DOT-based therapies in AML.

Persistence is a key goal and a major challenge of adoptive cellular immunotherapy. Aiming to determine the sustained functionality and potency of (CAR-or mock-) DOTs after >40 days of controlling AML progression, we then performed a tumor re-challenge experiment. Disease-free mice that eliminated the previous AML graft (Fig 5) , either under all CD123CAR-DOT treatments or under mock-DOTs + daily IL-15, were rechallenged with an additional AML-PDX LUC i.v. infusion at day 47 ( Fig 6A) . The BM of leukemia patients is exposed to several cycles of chemotherapy and immunosuppressants, which alters the status of normal T cells 5, 39, 40 . Particularly in AML patients, T cells have been characterized with an exhausted phenotype at relapse 26 . In this context, allogeneic T cells represent an attractive alternative, since circulating T cells from HDs have not suffered disease-or therapy-induced dysfunction. While various groups have reported the generation of allogeneic T-cells, these cells must undergo genetic manipulation, generally CRISPR/Cas9 editing, to eliminate the endogenous T-Cell Receptor (TCR) since it would otherwise drive a (potentially severe) graft-versus-host reaction. Elegant studies have reported the feasibility of these TCR KO CAR-T cells in preclinical models and even in pediatric patients [41] [42] [43] . However, a relevant recent paper has reported that TCR elimination in CAR-T cells leads to a decrease in persistence 44 . Furthermore, from a clinical point-of-view, CRISPR/Cas9 handling would still have to solve complex regulatory requirements.

Since the vast majority of  T cells are HLA-independent 45 , they do not require genetic manipulation to be used as allogeneic therapies. It was with this purpose that we previously developed DOT cells, a V1 T cellenriched cell product characterized by the upregulation of multiple activating/ cytotoxicity-associated NK-cell receptors (NKG2D, DNAM-1, NKp30, NKp44) , and showed their anti-leukemic potential 10, 14 . However, our previous data in AML xenograft models left a significant margin for improvement in terms of control of tumor burden 15 . Here we investigated whether DOT transduction with a CD123-directed CAR would improve efficacy and lead to complete and durable leukemia remissions. We show that, compared (side-by-side) with control (mock-)DOTs, CAR123-DOTs are substantially more potent at eliminating AML blasts (both cell lines and primary samples) in vitro; release increased levels of key cytokines involved in immune orchestration and amplification of the anti-tumor response; and are more efficient at controlling tumor growth in vivo, in AML-PDX experiments conducted over 70 days.

We also found that upon administration of IL-15 in our AML-PDX models, CD123CAR-DOTs (and also mock-DOTs) persisted better, thus allowing a single dose to maintain mice free of leukemia. Critically, daily-infused IL-15 enabled CD123CAR-DOTs to sustain their anti-leukemic activity for more than 70 days, even after AML re-challenge. These results are in agreement with recent elegant publications showing CAR-V1 T-cell efficacy and the adjuvant effect of IL-15 in B-cell lymphoma and hepatocellular carcinoma models 12, 46 . Only the clinical setting can establish the real benefit of IL-15 co-administration (potentially with an inducible "switch off" system) with CD123CAR-DOTs. Obviously, our (and other) pre-clinical mouse xenograft models lack endogenous human IL-15; thus, basal circulating IL-15 levels in patients could suffice to sustain CD123CAR-DOT persistence and activity/efficacy in the clinical setting. Importantly, lymphodepletion regimens that are used prior to CAR T-cell infusions were shown to increase the levels of IL-15 in patients 47 .

Therefore, although described as safe in non-human primates 48 , the need for exogenous (adjuvant) IL-15 should be carefully examined since it caused some toxicities in a recent clinical trial in cancer patients 49 . This notwithstanding, this clinical trial employed a continuous bolus of IL-15 as single therapy, and thus, lower and/ or intermittent IL-15 dosing may be a promising solutions 50, 51 .

An important final aspect to discuss is the potential advantage of using DOTs as effector cells for CAR transduction. Compared with conventional -dominated T-cell products, DOTs offer several advantages: first and foremost, the previously mentioned suitability for allogeneic use, without any need for additional genetic engineering 52 ; additionally, the lack of T-cell exhaustion mediated by the immune checkpoint PD-1 (absent in DOTs 11 and CD123CAR-DOTs, see Fig. 1E ), and the upregulation of a NK-associated cytotoxicity machinery (including DNAM-1, NKp30 and NKp44) 10,14 that may be critical in the advent of CAR antigen loss as previously observed with CD19 in B-ALL 6 . Importantly, this enhanced NK-like cytotoxicity is also an advantage over other  T cell-based products being developed for adoptive immunotherapy of cancer [7] [8] [9] 12, 46 . On the other hand, in comparison with NK cells, which obviously share such activating NK-cell receptors, DOTs offer as key advantages 7, 8, 53 the previously documented 11 absence of inhibitory KIRs, namely KIR2DL1, KIR2DL2, KIR2DL4, KIR2DL5A and KIR3DL1, and the additional input of TCR-dependent activation and expansion (up to very high yields as reported 10, 14 ) . In fact, the presence of a stochastically recombined and highly polyclonal TCR repertoire, allowing HLA-unrestricted recognition of stress-induced molecules 8 , may also counteracts tumor immune evasion (via CAR antigen loss or HLA downregulation, for example). Moreover, the "trophic" (homeostatic) signals received through  TCR binding to butyrophilins constitutively expressed in multiple tissues 54 may be beneficial for in vivo persistence, and may underlie the recent description of a striking V1  T cell-associated CD19CAR-T cell expansion (from a very low initial frequency), over 10 years in a disease-free CLL patient 55 . Furthermore, although allogeneic CD19-directed CAR-NK cells have recently shown promising clinical results 56 , their "off-the-shelf" implementation may be difficult due to the reported substantial decrease in viability after the freezing/thawing process 57, 58 , which contrasts with the robustness we observed with CD123CAR-DOTs. We therefore strongly believe that CAR-DOTs combine a set of properties that may revolutionize allogeneic cell immunotherapy of hematological (and possibly also solid) cancers in the near future.

We are indebted with Dr. Talía Velasco-Hernández for technical support with IL-15 Cytokine array determination in supernatants obtained from 4 donors of CAR-DOTs/mock-DOTs exposed to 2 different AML primary samples for 48h. Relative expression was normalized to mock-DOT levels. *p<0.05, **p<0.01, ***p<0.001. 

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

CD19 CAR T cell product and disease attributes predict leukemia remission durability

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer

Cancer immunotherapy with γδ T cells: many paths ahead of us

Delta one T cells for immunotherapy of chronic lymphocytic leukemia: Clinical-grade expansion/differentiation and preclinical proof of concept

Costimulation of γδ TCR and TLR7/8 promotes Vδ 2 T-cell antitumor activity by modulating mTOR pathway and APC function

Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models

Epigenetic modulation of immune synaptic-cytoskeletal networks potentiates γδ T cell-mediated cytotoxicity in lung cancer

Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Acute myeloid leukemia: current progress and future directions

How I treat acute myeloid leukemia in the era of new drugs

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

Cells for Acute Myeloid Leukemia: State of the Art and Future Directions

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia

Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells

Plasticity in growth behavior of patients' acute myeloid leukemia stem cells growing in mice

Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing

IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin

Normality sensing licenses local T cells for innate-like tissue surveillance

The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

Targeting cardiac fibrosis with engineered T cells

CAR T cells produced in vivo to treat cardiac injury. Science (80-. )

CAR T cells for infection, autoimmunity and allotransplantation

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Naïve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers

Lingering effects of chemotherapy on mature T cells impair proliferation

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Six-of-the-best: Unique contributions of γδ T cells to immunology

Off-the-shelf Vδ 1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma

Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens

Safety and immunologic effects of IL-15 administration in nonhuman primates

IL-15 in the Combination Immunotherapy of Cancer

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: Implications for combination therapy with antitumor antibodies

The potential role of gd T cells after allogeneic HCT for leukemia

Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells

The Innate Biologies of Adaptive Antigen Receptors

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells

NK cell-based cancer immunotherapy: from basic biology to clinical development

BLI at the indicated timepoints. (C) Total radiance quantification (p/sec/cm 2 /sr) at the indicated timepoints

Tumor burden was monitored by FACS in BM at day 30. (E) Dot plots of representative V1  and V2  T cells determined in CAR-DOT/ mock-DOT-treated mice in BM at day 30. (F) Total  T cells were monitored by FACS in BM at day 30

Figure 6. A single-dose of CD123CAR-DOT cells plus daily IL-15 sustain the ability to control AML progression upon re-challenge in a PDX model. (A) Schematic of the tumor re-challenge AML-PDX LUC experiments. Mock-DOTs plus daily IL-15-treated mice and CAR-DOTs-treated mice

CAR-or mock-) DOT cell infusion. (B) IVIS imaging of tumor burden monitored by BLI at the indicated timepoints. (C) Total radiance quantification (p/sec/cm 2 /sr) over time in mice re-challenged with AML-PDX LUC . Tumor burden was monitored at endpoint analysis (day 70) by FACS in BM (D) and PB (E)